Additional file 1 of Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
Creators: name: Chen, Sunnia T.
name: Azali, Leylah
name: Rosen, Lindsay
name: Zhao, Qiuhong
name: Wiczer, Tracy
name: Palettas, Marilly
name: Gambril, John
name: Kola-Kehinde, Onaopepo
name: Ruz, Patrick
name: Kalathoor, Sujay
name: Rogers, Kerry
name: Kittai, Adam
name: Grever, Michael
name: Awan, Farrukh
name: Byrd, John C.
name: Woyach, Jennifer
name: Bhat, Seema A.
name: Addison, Daniel
Publisher: name: figshare
Year: 2022
Subjects: subject: Medicine
subject: Cell Biology
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: Science Policy

description: Additional file1: Table S1 Long-term rates, time to development, and management of new or worsened hypertension (HTN) during acalabrutinib therapy. Table S2 Distribution of maximum SBP increase from baseline, %. Table S3 Development of new or worsened hypertension among patients based on concomitant obinutuzumab treatment. Table S4 Univariable predictors for the development of new or worsened hypertension (n=280). Table S5A Multivariable predictors for the development of new or worsened hypertension, in patients not previously treated with ibrutinib (n=208). Table S5B Multivariable predictors for new hypertension alone (n=115).* Table S5C Multivariable predictors for worsened hypertension alone (n=165).*Table S6A Univariate analysis of association of single-agent baseline antihypertensive therapy (n=115) to development of worsening hypertension (HTN), excluding those on other anti-HTN medications (n=1‡). Table S6B Multivariate analysis of development of worsening hypertension (HTN), considering acalabrutinib users on single-agent baseline beta blocker therapy. Table S6C Multivariate analysis of development of worsening hypertension (HTN), considering acalabrutinib users on any single-agent baseline antihypertensive therapy. Table S6D Change in blood pressure among subjects requiring the addition of new or additional antihypertensive class within the 1st year of acalabrutinib therapy. [From the 43 patients started on a new or additional antihypertensive, 17 patients saw the addition within 12 months of acalabrutinib initiation, of which 10 were treated with the addition of a single antihypertensive drug, 9 had pre- and post-antihypertensive blood pressures; another 7 (out of 17) required initiation of ≥ 2 antihypertensives and had available blood pressure measures pre- and 12 months post-initiation of the first antihypertensive added during acalabrutinib use.] Table S7 Occurrence of major adverse cardiovascular events (MACE), by acalabrutinib-related hypertension (HTN) status. Table S8A Multivariable analysis for the development of MACE during acalabrutinib use, considering development of new or worsened HTN as a time-dependent covariate.*Table S8B Multivariable analysis for the development of AF during acalabrutinib use, considering development of new or worsened HTN as a non-time-dependent covariate. Table S9 Cumulative incidence of new, predicted, and grade 3 or more HTN over time. Figure S1 Study Cohort Diagram. From a registry of all patients with hematologic malignancies treated with acalabrutinib over a 6-year period, those with available blood pressures were included. HTN, hypertension. Figure S2. Risk of AF development, in relationship of observed peak SBP increase within 12 months of acalabrutinib initiation. AF, atrial fibrillation; SBP, systolic blood pressure. Figure S3. Cumulative incidence of disease progression or death among those remaining on acalabrutinib beyond 90 days (landmark) alone, without initial progression or death, by new or worsened hypertension status.